Ziff Capital Partners

Corner Therapeutics is a biotechnology company focused on immunotherapy research. It specializes in developing technologies that hyperactivate dendritic cells to induce robust and durable T-cell responses, aiming to provide lifelong immunity against various cancers and infectious diseases.

Platelet BioGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2014. It specializes in the production of donor-independent human platelets derived from pluripotent stem cells for clinical applications. The company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. These bioreactor-produced platelets are distributed to hospitals and blood banks, providing essential therapeutic resources to patients globally. Through its innovative approach, Platelet BioGenesis is contributing to advancements in biotechnology and the field of transfusion medicine.

Founded in 2017, Mighty Networks is a SaaS platform that enables creators and brands to build, engage, and monetize their online communities. It offers customizable tools for creating private spaces, facilitating member engagement, and integrating with other services, all under the creator's brand and available on every platform.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Founded in 1999, SomaLogic specializes in the discovery, development, and commercialization of life science research tools and clinical diagnostic products centered around its proprietary SOMAmer/SOMAscan technology. This platform enables protein measurement at scale, facilitating biomarker discovery for various diseases, drug development, and clinical diagnostics.

Imvax, Inc. is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative, patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers with significant unmet medical needs. Incorporated in 2015, Imvax's primary product, IGV-001, is an autologous tumor cell vaccine designed to harness the patient's immune system to generate a robust response against tumor cells. The company employs advanced methodologies, including patient cell harvest and treatment, immunogenic cell death, and activation of both the innate and adaptive immune systems, to enhance therapeutic outcomes. Through its novel approach, Imvax aims to provide effective treatments for patients facing challenging cancer diagnoses.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Imvax, Inc. is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative, patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers with significant unmet medical needs. Incorporated in 2015, Imvax's primary product, IGV-001, is an autologous tumor cell vaccine designed to harness the patient's immune system to generate a robust response against tumor cells. The company employs advanced methodologies, including patient cell harvest and treatment, immunogenic cell death, and activation of both the innate and adaptive immune systems, to enhance therapeutic outcomes. Through its novel approach, Imvax aims to provide effective treatments for patients facing challenging cancer diagnoses.

Platelet BioGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2014. It specializes in the production of donor-independent human platelets derived from pluripotent stem cells for clinical applications. The company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. These bioreactor-produced platelets are distributed to hospitals and blood banks, providing essential therapeutic resources to patients globally. Through its innovative approach, Platelet BioGenesis is contributing to advancements in biotechnology and the field of transfusion medicine.